Medical Genetics- Autosomal Dominant Disorders [Video Lecture]
This video lecture is the part of the lecture on single gene disorder or Mendelian disorder (inheritance). The lecture contains the classification of genetic...

By: Janak Lecture Series

Read the original here:
Medical Genetics- Autosomal Dominant Disorders [Video Lecture] - Video

Recommendation and review posted by Bethany Smith

The Sims 3 - Perfect Genetics Challenge - Pt1 - Introductions
If you like this video please leave a thumbs up, it really helps Open fully for links additional info and social media links I am a social media floo...

By: xSimSugar

Continue reading here:
The Sims 3 - Perfect Genetics Challenge - Pt1 - Introductions - Video

Recommendation and review posted by Bethany Smith

By RTT News, February 10, 2015, 04:32:00 PM EDT

(RTTNews.com) - Biotechnology company Seattle Genetics Inc ( SGEN ) on Tuesday reported fourth-quarter net loss of $26.7 million or $0.22 per share compared with a loss of $15.7 million or $0.13 per share last year.

Revenues for the quarter were $74.3 million compared with $67.4 million in the prior year.

Analysts polled by Thomson Reuters estimated a loss of $0.25 per share on revenues of $69.1 million for the quarter. Analysts' estimates typically exclude special items.

Total expenses for the quarter rose to $102 million from $83 million last year, due mainly to higher research costs.

For the full year 2015 , the company expects revenues from sales of key product ADCETRIS of $200 million to $210 million and revenues from collaboration and license agreements of $60 million to $70 million.

Analysts expect revenues of $332.9 million for 2015.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Read the rest here:
Seattle Genetics Loss Narrower Than Estimates

Recommendation and review posted by Bethany Smith

How Origami is Inspiring Scientific Creativity, with BYU and Origami Artist Robert Lang
Ancient origami inspires surprising modern innovations like solar arrays for NASA and a microscopic nanoinjector that can be used in gene therapy. These origami-inspired designs from Brigham...

By: BYU

Read the rest here:
How Origami is Inspiring Scientific Creativity, with BYU and Origami Artist Robert Lang - Video

Recommendation and review posted by Bethany Smith

Cell Therapy, which is based in the Welsh capital Cardiff, says the medicine has the potential to reduce scarring of the heart muscle caused by a heart attack or failure.

Chief executive Ajan Reginald, who was previously at Roche, said crowd funding was a quick way to raise money for final stage trials or commercial launches.

Loading article content

"It was very fast and very efficient," he said. "We have spent five per cent of our time on fundraising, which enables me to spend 95 per cent of my time on the business."

The company's founder Martin Evans shared the 2007 Nobel Prize for medicine for groundbreaking stem cell research.

Cell Therapy used website Crowdcube to raise nearly three times its original target from more than 300 investors.

Mr Reginald said the backers included investment bankers, hedge fund employees and scientists.

"Crowd funding allows investors to look in detail at a company in their own time," he said, adding that some 10,000 investors had seen the pitch.

The company plans to publish data from clinical trials of the drug, called Heartcel, next month, before final stage trials with a view to a launch in 2016.

Go here to read the rest:
Biotech firm Cell Therapy claims crowdfunding record with heart drug

Recommendation and review posted by simmons

Biotechs may be flush with cash, thanks to the ol bullish IPO market and an uptick in venture funding. But startups remainon the lookout for alternative funding models with crowdsourcing front and center.

This makes British biotech startup Cell Therapyparticularly interesting,itjustraised 689,246 or a bit over$1 million to launch a stem cell therapy for heart failure. This is one of the highest life sciences-related crowdfunding efforts topped only by Scanadu, whose handheld consumer diagnostic tool raised $1.6 million in Indiegogo.

Cell Therapy, which was founded by 2007 Nobel Prize winner Martin Evans, raised the funding on thesite Crowdcube exceeding its goal of 250,000 with backing from nearly 300 investors. It ceded a mere 0.39% in equity to the backers thatinclude investment bankers, hedge fund employees and scientists, CEO Ajan Reginald said.

It was very fast and very efficient, Reginaldtold Reuters. We have spent 5 percent of our time on fundraising, which enables me to spend 95 percent of my time on the business.

Crowdfunding is increasingly becoming an option for early stage biotechs that want to sidestep the traditional venture-backed approach. On one hand, its a relatively simple means to raise a large amount of seed capital but on the other, there are many more (potentially irate) investors to answer to when a companys in its nascence.

New York-based Poliwoggs entire premise is on bringing crowdfunding to healthcare with aims to help companies raise fundsfrom accredited investors beyond the seed stage, with rounds ranging from $2 million to $10 million mark.Notably, ithas its own regenerative medicine fund.

Part of the idea here is that people want to invest in the things they care about, but they havent always had the opportunity to invest in them, CEO Greg Simon told MedCity News.Were giving people the opportunity to put their money where their passion is.

Thats all fine and good to have a passion for a cause, but the traditional accredited investor whos enmeshed in a crowdfunding effort may still not understand the intricacies of what it takes to get results or a return in a tricky field like regenerative medicine.

John Carroll over atFierce Biotechopined that crowdfunding wont make a significant dent in the approach to life sciences crowdfunding. Stem cell therapy, after all, generated tons of media pomp and flair a decade ago, but has yet to deliver on many of its curative promises from back then. VCs are often burnt and reticent, and investors on crowdfunding sites will likely be, as well. Carroll says:

Visit link:
Cell Therapy may have just raised $1M, but will crowdfunding have a lasting place in biotech?

Recommendation and review posted by simmons

Episode 5: Living With a Spinal Cord Injury
Host Katrina Smith interviews Priya Ray, an artist and musician who is raising money to get a Handicapable Van. Help Priya Ray get a Handicapable Van by clic...

By: Living With

Here is the original post:
Episode 5: Living With a Spinal Cord Injury - Video

Recommendation and review posted by sam

Kansas City, MO (PRWEB) February 09, 2015

One in five Americans will develop heart failure in their lifetime. It is the number one cause of hospitalization for adults over 65. The cost to treat heart failure is $32 billion and expected to double by 2030. There is no doubt heart failure is a significant health problem. The good news is proper care and treatment can dramatically improve a patients outcome and potentially promising new treatments are on the horizon.

February 8-14, 2015 is National Heart Failure Awareness Week. Saint Lukes Mid America Heart Institute, in Kansas City, Missouri specializes in treating heart failure and other complex cardiovascular conditions and has long been one of the leaders in cardiovascular care not only in the Midwest, but across the country.

Heart failure occurs when the heart is unable to efficiently move blood to the rest of the body either due to thickening or weakness. Onset can come from a variety of causes including heart attack, viral illness, abnormal heart valves, genetic traits and even after pregnancy. Symptoms can be subtle; shortness of breath, fatigue, dizziness, swelling in the legs and or stomach.

The good news is a variety of treatments are available and proper care and treatment can dramatically improve symptoms and quality of life for patients.

Treatments include:

The exciting news for patients is we have promising treatments currently in the research phase of development, said Bethany Austin, M.D., Associate Medical Director of the Advanced Heart Failure Program at Saint Lukes Mid America Heart Institute. These treatments range from clinical trials involving catheter based treatments, treatment of sleep apnea, and gene therapy with stem cells for damaged heart muscles. In addition, there is a new medication which has shown in recent trials to provide significant benefit to heart failure patients compared to standard therapy although it is not yet commercially available. All of these offer new hope to heart failure patients.

Saint Lukes offers a multidisciplinary heart team, including the regions only team of cardiologists board certified in Advanced Heart Failure and Cardiac Transplant, cardiothoracic surgeons, and critical care anesthesiologists.

The Saint Lukes Heart Failure Program also features:

In 2014, The Joint Commission awarded Saint Lukes Hospital Advanced Certification in Heart Failure. Only 53 other hospitals in the United States currently have Advanced Heart Failure Certification. Saint Lukes Hospital also received the Get With The GuidelinesHeart Failure Gold-Plus Quality Achievement Award for implementing specific quality improvement measures outlined by the American Heart Association/American College of Cardiology Foundation secondary prevention guidelines for heart failure patients.

See the original post here:
Saint Lukes Mid America Heart Institute Offers Tips & Treatments For Heart Failure Awareness Week 2015

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Inherited gene variations tied to treatment-related hearing loss in cancer patients St. Jude Childrens Research Hospital scientists have identified inherited genetic variations associated with hearing loss in young cancer patients treated with cisplatin, a drug widely used to treat adults with cancer

Newswise (MEMPHIS, TENN. February 9, 2015) St. Jude Childrens Research Hospital investigators have discovered inherited genetic variations that are associated with rapid hearing loss in young cancer patients treated with the drug cisplatin. The research appears in the current online issue of the scientific journal Nature Genetics.

Cisplatin is one of the most widely used anti-cancer drugs and is a mainstay of treatment for children and adults with many types of brain and other solid tumors. But in some patients the drug causes debilitating side effects, including severe hearing loss. The risk factors involved are not completely understood. Even for children receiving uniform therapy, there is substantial variability in their hearing damage after cisplatin treatment, and we suspect this has to do with differences in patients genetic make-up, said co-corresponding author Jun J. Yang, Ph.D., an assistant member of the St. Jude Department of Pharmaceutical Sciences.

Researchers checked the DNA of 238 young brain tumor patients for more than 1.7 million common genetic variations. Variations in a gene named ACYP2 were associated with as much as a four-fold greater risk of cisplatin-related hearing loss. The screening is among the first to survey the genetic landscape for clues to help explain why the risk of cisplatin-related hearing loss varies so widely among patients. St. Jude is a leader in research to improve medication safety and effectiveness. Its research aims to understand how inherited genetic variations affect the way individuals metabolize and respond to drugs.

This is an important first step in being able to pinpoint patients who are at higher risk of developing cisplatin toxicity and to learn how to better manage that risk, said co-corresponding author Clinton Stewart, Pharm.D., a member of the St. Jude Department of Pharmaceutical Sciences.

The association between the high-risk ACYP2 variants and cisplatin-related hearing loss was confirmed in a separate group of 68 young brain tumor patients. The link was independent of other risk factors for cisplatin-related hearing loss, including patient age and radiation therapy.

Twenty-four of the 306 patients in this study had at least one copy of the high-risk ACYP2 variant. All 24 patients had measurable hearing loss that occurred as early as weeks after beginning cisplatin therapy. Overall, however, the ACYP2 variant explained a relatively small proportion of hearing damage. Just 12.4 percent of the 194 patients in this study with cisplatin-related hearing loss carried the ACYP2 variant.

This suggests that other genes also contribute to the risk of hearing loss and are yet to be identified, Yang said. Further research is needed to understand how the ACYP2 variations modify the risk facing patients of cisplatin toxicity.

More:
Inherited Gene Variations Tied to Treatment-Related Hearing Loss in Cancer Patients

Recommendation and review posted by Bethany Smith

Neuroscientists at the Royal College of Surgeons in Ireland have made a major breakthrough in uncovering why epilepsy occurs.

The research focuses on understanding what controls gene activity in epilepsy and may also help to explain why epileptic states can be so persistent. The study will be published next month in the neurology journal Brain and is the first of its kind.

Epilepsy affects about 37,000 people in Ireland and one of the authors believes the study could potentially offer new targets for reversing the condition.

Given that epilepsy is often associated with altered levels of genes in the brain, the researchers looked for a chemical change to DNA called methylation, which acts as a long-lasting on/off switch for gene activity and thought to be one way that brain cells store biochemical memories.

More than 30,000 gene sites were studied as part of the research project using brain tissue from patients with epilepsy, including many not previously linked to the condition.

The research found in some cases, the more DNA methylation that occurred, the more gene activity was turned off. It also found that certain types of genes are more likely than others to be under this type of control.

Lead author of the study, Suzanne Miller-Delaney, said: It specifically aligns deterioration of parts of the brain with structural changes in patient DNA and gene activity.

The study can help us to understand what is controlling gene activity in epilepsy and why the epileptic state can be so persistent.

David Henshall from the RCSI Department of Physiology and Medical Physics, and the principal investigator of the project, said: This study could potentially offer new targets for reversing epilepsy once established.

The research project was supported by a grant from Epilepsy Ireland, The Health Research Board, and Science Foundation Ireland.

More here:
Neuroscientists make major breakthrough in epilepsy study

Recommendation and review posted by Bethany Smith

Bridges Middle School Student Explains Genetic Engineering

By: BridgesAcademy2E

See the original post here:
Bridges Middle School Student Explains Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

David Baltimore (Cal Tech) Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV
http://www.ibiology.org/ibioseminars/microbiology/david-baltimore-part-2.html Lecture Overview: In this set of lectures, I describe the threat facing the wor...

By: iBiology

More here:
David Baltimore (Cal Tech) Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV - Video

Recommendation and review posted by Bethany Smith

Research scientists (from left) Dr Jim Faed, Vicky Nelson and Dr Paul Turner talk about the possibilities of finding a cure for type 1 diabetes, during the Lion's Lark in the Park at the Dunedin Botanic Garden yesterday. Photo by Gregor Richardson.

Cell biologist, haematologist and project leader Dr Jim Faed, of the University of Otago, made the promise during the Lion's Lark in the Park event at Dunedin's Botanic Garden yesterday, which aimed to help raise some of the $2.46 million needed to run the trials.

Dr Faed said their research involved trials using stem cells taken from the bone marrow of people with type 1 diabetes, and using them to stimulate insulin production.

The cells appeared to be able to ''turn off'' the auto immune response that causes type 1 diabetes, he said.

''We see this as the low hanging fruit of research into a cure for type 1 diabetes because it has already been done once before.''

Trials had already been carried out on mice and humans. It just needed fine tuning, he said.

Much of the funds raised would go towards the Spinal Cord Society which will develop its stem cell production facilities in Dunedin, so that patients' own cells can be grown and tested in clinical trials.

''It's the only method that's attacking the cause of diabetes. Most of the other treatments are basically designed to manufacture insulin artificially.

''What we are looking for is a cure, not just support of people with the disease.

''This will be a sustained cure that doesn't require top ups.''

Go here to see the original:
Stem cells cure hope for diabetes

Recommendation and review posted by Bethany Smith

FAQ Part 4: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS)
The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEse...

By: MSSocietyCanada

More here:
FAQ Part 4: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) - Video

Recommendation and review posted by Bethany Smith

The Human Genome Unlocked
The Aspen Health Forum, 2009. With the mapping of the human genome complete, scientists are hoping to use stem cell therapy and related interventions to alleviate or even cure diseases. What...

By: The Aspen Institute

Originally posted here:
The Human Genome Unlocked - Video

Recommendation and review posted by Bethany Smith

Genetics Tutorial - (Binnies Mods 2.0)
There #39;s been some major changes in to Binnie #39;s plugins for Forestry and Genetics is one that #39;s brand new to the scene. The genetic machines you may be familiar with are long gone and have been...

By: The MindCrafters

More:
Genetics Tutorial - (Binnies Mods 2.0) - Video

Recommendation and review posted by Bethany Smith

No More Room in Hell - Gene therapy vs. immunity - CheetahPoizon
Enjoy the video ?? Hit the like button =) game name: No More Room in Hell steam link: http://store.steampowered.com/app/224260/ price: free version: 1.0.9.3.

By: CheetahPoizon

Read the rest here:
No More Room in Hell - Gene therapy vs. immunity - CheetahPoizon - Video

Recommendation and review posted by Bethany Smith

Regenerative Medicine | Oklahoma City, OK Dr. Darryl D. Robinson
If you #39;re in the Oklahoma City area, come visit Dr. Darryl D. Robinson and discover the power of regenerative medicine. Call 405-703-4950 or visit us online ...

By: Longevity Joint-Spine-Pain

Go here to see the original:
Regenerative Medicine | Oklahoma City, OK Dr. Darryl D. Robinson - Video

Recommendation and review posted by sam

#BeingAfricanCaribbean
What does #BeingAfricanCaribbean mean to you? There are many positive things we could say, but unfortunately #BeingAfricanCaribbean means that, if I were in ...

By: ACLT Charity

Continue reading here:
#BeingAfricanCaribbean - Video

Recommendation and review posted by Bethany Smith

12:00 07 February 2015

Abdullah Moallim

Chris Spencer survived a debilitating disease thanks to a bone marrow transplant facilitated by the Anthony Nolan blood cancer charity

Archant

The general manager of a sports centre, who owes his life to a bone marrow transplant, has urged young men to sign up to be future donors.

Email this article to a friend

To send a link to this page you must be logged in.

Chris Spencer, 49, who works at the Everyone Active Sports Centre in Harrow Lodge Park, Hornchurch, hosted a bone marrow recruitment event to give potential donors the chance to join the Anthony Nolan register.

Chris developed myelodysplastic syndrome (MDS) in 2013 and required a lifesaving bone marrow transplant.

The transplant was arranged by Anthony Nolan and now Chris is keen to raise awareness.

Read more:
Transplant survivor inspires bone marrow donor registration drive in Hornchurch

Recommendation and review posted by Bethany Smith

Stemologica Review - A Harmless Way To Fight Skin Aging Using Stemologica
Click the link below to get a risk free trial; http://skincarebeautyshop.com/go/have-your-stemologica-free-trial/ Read the Terms and Condition before you ord...

By: Yvan B.

See more here:
Stemologica Review - A Harmless Way To Fight Skin Aging Using Stemologica - Video

Recommendation and review posted by Bethany Smith

FAQ Part 2: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS)
The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEsenchymal Stem cell therapy for CAnadian.

By: MSSocietyCanada

See the rest here:
FAQ Part 2: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) - Video

Recommendation and review posted by Bethany Smith

Knee arthritis; 2 years after stem cell therapy by Harry Adelson, N.D.
Patricia describes her outcome two years after bone marrow and adipose stem cell therapy for her arthritic knee by Harry Adelson, N.D. http://www.docereclinics.com.

By: Harry Adelson, N.D.

See the rest here:
Knee arthritis; 2 years after stem cell therapy by Harry Adelson, N.D. - Video

Recommendation and review posted by Bethany Smith

Genetic Engineering cDNA
FM - .

By: Gyanvani Sangamam

Read more from the original source:
Genetic Engineering cDNA - Video

Recommendation and review posted by Bethany Smith

Crazy Cow - Blue Chip Genetics - IDW
Check out this great video about the successful team of Dianna and Dean Malcolm of Blue Chip Genetics and Crazy Cow in Print.

By: The Bullvine

Continued here:
Crazy Cow - Blue Chip Genetics - IDW - Video

Recommendation and review posted by Bethany Smith